Blog

Vein Finder Market Growth and Forecast (2024 – 2032)

The global vein finder market is projected to expand from USD 49.15 million in 2023 to over USD 113.24 million by 2032, with a compound annual growth rate (CAGR) of 8.7% from 2024 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5126

Report Highlights:

• Near-infrared technology led the vein finder market with a 57% share in 2023.
• Tabletop models were the most popular type of vein finder, capturing 55% of the market share in 2023.
• Hospitals and clinics accounted for the largest share of the market, with 62% in 2023.
• The integration of advanced technology is having a significant impact on the vein finder market.

As the global population ages, the demand for vein finders is expected to rise. The World Health Organization predicts that by 2050, the number of people aged 60 and older will double to 2.1 billion, and those 80 and older will triple to 426 million. This growing aging population will face more health challenges, including difficulty locating veins, driving the need for improved vein finding technology.

Vein finders are devices used by healthcare professionals to locate veins in patients’ bodies. They use various technologies, such as near-infrared light, to make veins visible, which is especially helpful for patients with challenging vein visibility, like children, elderly people, or individuals with darker skin tones.

These devices are crucial in procedures like drawing blood, inserting IV lines, and administering medications. They help reduce patient discomfort, minimize complications like bruising or multiple needle sticks, and improve the overall efficiency of medical procedures.

The rise in unsafe injection practices, which contribute to infections like Hepatitis B, Hepatitis C, and HIV, is also driving the adoption of vein finders. The World Health Organization reports that approximately 1.7 million people contract Hepatitis B, 315,000 get Hepatitis C, and over 33,800 acquire HIV due to unsafe injections. Vein finders can help reduce these infections and ease the burden on hospitals and patients.

Vein finders are used in various medical settings, including hospitals, clinics, emergency rooms, and even at-home healthcare. They are particularly valuable when vein visibility is poor or when medical staff need to work quickly and accurately.

The increasing popularity of mobile health is expected to further boost the use of vein finders in hospitals and clinics. In 2020, over 350,000 health apps were available for download, and newer apps with advanced technology are now capable of scanning patients’ skin to locate veins.

A research study by the National Institutes of Health, involving 242 participants, assessed the effectiveness of a newly developed vein finder in visualizing and mapping veins on the arm and dorsal hand. The study considered factors like age, skin tone, gender, and arm circumference in its evaluation.

The vein finder market is set for steady growth due to the increasing demand for minimally invasive procedures, more medical procedures requiring venous access, and technological advancements leading to more portable and user-friendly devices. Additionally, the aging population, which often faces challenges in vein access, is driving the demand for these devices.

As healthcare providers continue to recognize the benefits of accurate vein visualization for improving patient care and procedural efficiency, the vein finder market is expected to experience sustained growth.

Recent Developments:

In 2022, Light-emitting diodes (LEDs) became a popular, cost-effective option in the vein finder market. Compared to other devices, LED vein finders were more affordable while also being lightweight and portable. Their versatility was further enhanced by the availability of different colors, making them suitable for various skin tones and ensuring better vein visibility across diverse patient groups. LED vein finders were particularly useful in pediatric care, where their gentle, non-invasive nature and easy-to-use design made them ideal for young patients, allowing for smoother medical procedures.

In February 2021, AccuVein Inc. announced that the Infusion Nurses Society (INS) recommended the use of Near-Infrared (NIR) vein visualization technology during venipuncture procedures. This technology helps healthcare professionals assess veins on the skin’s surface, making it easier to choose the right vein for procedures like blood draws or IV insertions.

Key Companies in the Vein Finder Market:

• AccuVein Inc.
• Christie Medical Holdings, Inc.
• Veincas Ireland Ltd.
• Novarix Ltd.
• TradeMed.com
• Medline Industries, LP
• B. Braun Medical Inc.
• VINO Optics
• TransLite LLC
• Venoscope

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/vein-finder-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5126

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Hemato-Oncology Testing Market Growth and Key Players

The global hemato-oncology testing market was valued at $3.17 billion in 2023 and is projected to grow significantly, reaching an estimated $9.78 billion by 2033. This represents a robust compound annual growth rate (CAGR) of 12.4% from 2024 to 2033.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5123

Key Insights into the Hemato-Oncology Testing Market

• Service-based offerings led the market in 2023, accounting for 58% of the total share.
• Leukemia, a type of blood cancer, was the most common target in 2023, commanding 40% of the market.
• PCR (polymerase chain reaction) technology dominated testing methods, holding 45% of the market due to its exceptional accuracy and efficiency.

In 2024, non-Hodgkin lymphoma (NHL) is expected to represent about 4% of all cancer cases in the United States, with an estimated 80,620 new diagnoses and 20,140 deaths. Advances in early detection and treatment have contributed to declining NHL incidence and mortality rates.

What is Hemato-Oncology?

Hemato-oncology is a specialized field of medicine focused on diagnosing, treating, and managing blood cancers (like leukemia, lymphoma, and myeloma) and other related disorders. Specialists in this field employ various treatments, including chemotherapy, targeted therapy, immunotherapy, radiation therapy, and stem cell transplants, often collaborating with other medical experts to deliver the best patient care.

The Importance of Early Detection

Early diagnosis of cancers and blood disorders is crucial for several reasons:

• It allows treatments to begin sooner, significantly improving outcomes and, in some cases, achieving a cure.
• Early-stage detection reduces the likelihood of cancer spreading, simplifying treatment and enhancing survival rates.
• Patients benefit from improved quality of life and quicker recovery with early intervention.
• Untreated blood disorders can lead to complications like anemia or bleeding issues, further emphasizing the need for prompt diagnosis.
• Early detection also broadens treatment options, as many therapies are more effective in the initial stages. Additionally, early intervention can lower healthcare costs by reducing the need for more intensive, expensive treatments.

Impact on the Market

The growing need for cancer and blood disorder treatments is driving expansion in the hemato-oncology market. Pharmaceutical companies are investing in developing innovative drugs and therapies, while medical technology companies focus on creating advanced diagnostic tools to enable earlier and more precise detection. This rising demand is also increasing the need for highly trained hemato-oncology specialists, whose expertise is essential in delivering effective patient care.

As these conditions become more common and treatment options improve, the hemato-oncology market continues to grow, supported by advancements in medicine and technology.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/hemato-oncology-testing-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5123

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Chronic Lower Back Pain Market Growth, Future Trends and Forecast

The chronic lower back pain market was valued at $2.46 billion in 2023 and is expected to grow significantly, reaching $6.12 billion by 2033. This growth represents a strong annual growth rate of 9.52% from 2024 to 2033. One of the primary factors driving this growth is the rising elderly population suffering from arthritis, which is a major contributor to chronic lower back pain.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5156

Key Insights

• North America accounted for the largest share of the chronic lower back pain market, with 48.12% of revenue in 2023.
• Non-steroidal anti-inflammatory drugs (NSAIDs) made up more than 26% of the market revenue in 2023.
• The opioids segment holds the second-largest share and is expected to experience the fastest growth during the forecast period.
• The oral route of administration was the dominant method for treating chronic lower back pain in 2023.
• The topical segment is growing rapidly in the market.
• Retail and online distribution channels led the market in 2023.

Industry Overview

The chronic lower back pain (CLBP) market covers a wide range of activities, including research and development, drug manufacturing, disease monitoring, treatment, and post-treatment care. CLBP is defined as lower back pain that lasts for more than 12 weeks or three months, even after the initial injury or cause has been addressed. Over the past decade, the prevalence of CLBP in adults has increased by more than 100%, and as the population ages, this trend is expected to continue, affecting people of all ages, genders, and ethnicities. Key factors contributing to CLBP include aging, smoking, genetics, fitness level, weight gain, work-related activities, and mental health issues. Healthcare providers, pharmaceutical companies, pharmacies, research institutions, and assisted living facilities all contribute to the growth of the chronic lower back pain market.

Report Highlights

By Drug Class

In 2023, non-steroidal anti-inflammatory drugs (NSAIDs) were the leading drug class in the chronic lower back pain market. NSAIDs, including over-the-counter options like naproxen, ibuprofen, and diclofenac, are commonly used to relieve pain, inflammation, and fever. These drugs are often recommended for conditions such as back pain, muscle strains, and headaches, providing mild relief. Prescription-strength NSAIDs are also available, and they can be administered in pill form or as nasal sprays.

Opioids, which are stronger, prescription-only medications, held the second-largest market share and are expected to grow rapidly in the coming years. Opioids like morphine, oxycodone, and tramadol are used when other treatments are insufficient. Although potent, opioids come with risks and are generally reserved for more severe pain cases.

By Route of Administration

The oral route of administration was the most common in the chronic lower back pain market in 2023. Oral medications are convenient and non-invasive, making them easy for patients to take without needing injections or other complex procedures. This method improves patient compliance, simplifies treatment, and reduces healthcare costs. Additionally, oral drugs are generally well-absorbed, making dose calculations and administration straightforward.

The topical segment, which involves applying medications directly to the skin, is seeing significant growth. Topical treatments provide targeted, immediate pain relief and are easy to use. They also have a better safety profile than oral medications, with fewer side effects, though skin irritation at the application site can occur. Topical treatments are effective for various types of pain, including back, muscle, joint, and arthritis pain. For example, in April 2024, a new drug-free product, BackVive, was introduced. This over-the-counter patch uses micro-points that lightly penetrate the skin to relieve chronic back pain, showing substantial effectiveness in clinical trials.

By Distribution Channel

In 2023, the retail and online segments were the primary distribution channels for chronic lower back pain treatments. Retail pharmacies allow patients to consult with pharmacists directly, offering advice on medications, side effects, and alternatives. Online pharmacies also play a key role by providing cost-effective and convenient access to medications, improving patient adherence and reducing healthcare costs. These services ensure safer, more efficient medication delivery and contribute to better health outcomes.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/chronic-lower-back-pain-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5156

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Insights into the Multiple Sclerosis Market Diagnosis and Treatment Trends (2024 – 2032)

The global market for multiple sclerosis diagnosis and treatment is poised for steady growth. Valued at approximately USD 22.14 billion in 2023, it is projected to expand to around USD 30.28 billion by 2032, reflecting a compound annual growth rate (CAGR) of 3.4% during the forecast period.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5140

Key Market Highlights

• Advancing Technology in MS Care
  Recent technological advancements have transformed how MS is diagnosed and treated. Tools like magnetic resonance imaging (MRI) now provide highly detailed images of the brain and spinal cord, enabling doctors to detect early signs of MS and monitor disease progression more effectively.Innovative tests for cerebrospinal fluid have emerged, allowing the detection of specific biomarkers that differentiate MS from other neurological conditions. This precision in diagnosis ensures timely and appropriate treatment for patients.
• Economic Impact of MS
  MS imposes a significant economic burden globally, from healthcare costs to lost productivity. Efforts are underway to reduce these costs by improving early diagnosis and developing cost-effective treatment options.
• Relapse-Remitting MS Leads the Market
  Relapse-Remitting MS (RRMS) remains the most prevalent form of the disease, accounting for over 70% of the market share in 2023. Treatments targeting RRMS continue to drive market revenues.
• Medication as the Cornerstone of Treatment
  Medications dominated the market in 2023, representing 81% of the total share. These therapies aim to slow disease progression, reduce relapse frequency, and improve patients’ quality of life.
• Asia Pacific Emerges as a Growth Leader
  The Asia Pacific region is expected to be the fastest-growing market, with a projected CAGR of 7.0% during the forecast period, driven by increased awareness, improved healthcare infrastructure, and rising prevalence of MS.

Prevalence and Impact of MS

• An estimated 190 cases per 100,000 people in England, translating to 105,800 individuals, are affected by MS.
• MS is more common in women than men, with prevalence rates of 272 and 106 cases per 100,000, respectively.
• Women aged 50-59 are three times more likely to have MS compared to men of the same age group, with rates of 578 versus 184 cases per 100,000 population.
• The highest prevalence is observed in individuals aged 60-69, with rates of 598 cases per 100,000 for women and 228 cases per 100,000 for men.
• About 75% of MS diagnoses occur between ages 40 and 74, and the annual incidence in England ranges from 8 to 11 new cases per 100,000 population.

As prevalence rises globally, the need for advanced diagnostic tools and effective treatments becomes increasingly critical.

Driving Innovation in MS Treatment

Drug development and research are making strides in slowing MS progression and improving patient outcomes. For example:

• Sandoz’s Expansion in MS Treatment
  In June 2022, Sandoz launched Dimethyl fumarate HEXAL, a cost-effective generic treatment for RRMS in Germany, providing an alternative to the widely-used reference drug Tecfidera.
• Global Prevalence and Research Efforts
  An estimated 1.8 million people worldwide are living with MS. This rising number has spurred increased research and investment in understanding the disease, leading to better diagnostic tools and treatment options.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/multiple-sclerosis-diagnosis-and-treatment-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5140

We’ve prepared a service to support you. Please feel free to contact us at  sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare